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Abstract
The barrier separating mucosal and systemic compartments comprises epithelial cells, annealed by tight junctions, limiting
permeability. GUCY2C recently emerged as an intestinal tumor suppressor coordinating AKT1-dependent crypt-villus
homeostasis. Here, the contribution of GUCY2C to barrier integrity opposing colitis and systemic tumorigenesis is defined.
Mice deficient in GUCY2C (Gucy2c2/2) exhibited barrier hyperpermeability associated with reduced junctional proteins.
Conversely, activation of GUCY2C in mice reduced barrier permeability associated with increased junctional proteins.
Further, silencing GUCY2C exacerbated, while activation reduced, chemical barrier disruption and colitis. Moreover,
eliminating GUCY2C amplified, while activation reduced, systemic oxidative DNA damage. This genotoxicity was associated
with increased spontaneous and carcinogen-induced systemic tumorigenesis in Gucy2c2/2 mice. GUCY2C regulated barrier
integrity by repressing AKT1, associated with increased junction proteins occludin and claudin 4 in mice and Caco2 cells in
vitro. Thus, GUCY2C defends the intestinal barrier, opposing colitis and systemic genotoxicity and tumorigenesis. The
therapeutic potential of this observation is underscored by the emerging clinical development of oral GUCY2C ligands,
which can be used for chemoprophylaxis in inflammatory bowel disease and cancer.
Citation: Lin JE, Snook AE, Li P, Stoecker BA, Kim GW, et al. (2012) GUCY2C Opposes Systemic Genotoxic Tumorigenesis by Regulating AKT-Dependent Intestinal
Barrier Integrity. PLoS ONE 7(2): e31686. doi:10.1371/journal.pone.0031686
Editor: Mikhail V. Blagosklonny, Roswell Park Cancer Institute, United States of America
Received November 30, 2011; Accepted January 11, 2012; Published February 2 , 2012
Copyright:  2012 Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: These studies were supported by grants from the National Institutes of Health (NIH) (CA146033), the Pennsylvania Department of Health, and Targeted
Diagnostic and Therapeutics Inc. The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations or conclusions. Dr.
Garcia and Dr. Li were supported by NIH 5T32 GM08562. The funders had no role in study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: This study was partly funded by Targeted Diagnostic and
Therapeutics Inc. Dr. Waldman is the Chair (uncompensated) of the Scientific Advisory Board of Targeted Diagnostics and Therapeutics, Inc., which has a license to
commercialize inventions related to this work. Dr. Waldman is the Samuel M.V. Hamilton Endowed Professor. There are no patents, products in development or
marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the
guide for authors.
* E-mail: Scott.Waldman@Jefferson.edu
. These authors contributed equally to this work.
Introduction
The intestinal mucosa, from duodenum to rectum, represents
the largest physiological interface separating the environment from
the systemic compartment [1–3]. Indeed, the mucosal surface area
represents the most significant anatomic portal for systemic
exposure to environmental toxins and microorganisms [4]. These
exposures are prevented by the epithelial barrier, in part,
comprising a network of junctional complexes that anneal
membranes of neighboring enterocytes and thereby restrict
paracellular macromolecular exchange between mucosal and
systemic compartments [3]. While the molecular components of
tight junctions have been enumerated, signaling mechanisms
regulating dynamic programming of their steady-state concentra-
tions, assembly, and deployment remain incompletely defined [1–
3,5]. In that context, signaling by v akt murine thymoma viral
oncogene homolog (AKT) plays a central role in regulating barrier
dynamics [6–9]. Importantly, there is an emerging recognition of
the contribution of barrier dysfunction to local and systemic
diseases, including inflammatory bowel disease, diabetes, multiple
sclerosis, food allergy, asthma, systemic genotoxicity and malig-
nancies [1–3,10,11].
Guanylyl cyclase C (GUCY2C) is the intestinal receptor for the
endogenous paracrine hormones guanylin (GUCA2A) and
uroguanylin (GUCA2B) and the heat-stable enterotoxins (STs)
produced by diarrheagenic bacteria [12]. Upon ligand engage-
ment, GUCY2C converts cytosolic GTP to the second messenger
cyclic GMP (cGMP), activating effector pathways principally
through cyclic GMP-dependent protein kinase (PKG) [12].
GUCY2C signaling regulates intestinal fluid and electrolyte
balance through PKG-dependent activation of the cystic fibrosis
transmembrane conductance regulator (CFTR) [12]. Beyond fluid
and electrolyte balance, GUCY2C plays a central role in crypt-
villus dynamics, regulating enterocyte proliferation, differentiation,
DNA damage sensing and repair, and metabolism [12–16].
GUCA2A and GUCA2B are the most commonly lost gene
products in intestinal tumorigenesis, silencing GUCY2C signaling
early in transformation [17–19]. Moreover, eliminating GUCY2C
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expression in mice (Gucy2c2/2) potentiates genetic and carcinogen-
induced tumorigenesis [14,15]. These observations suggest that
GUCY2C regulates homeostatic programs along the crypt-surface
axis and silencing of this paracrine hormone system through ligand
loss contributes to initiation and progression of intestinal neoplasia
[12–16].
Coordinated regulation of homeostatic processes maintaining
the intestinal epithelium by GUCY2C is mediated by a molecular
mechanism in which cGMP suppresses AKT phosphorylation and
activation [15]. In turn, these homeostatic processes regulating
epithelial integrity are essential components of molecular pro-
grams supporting mucosal barrier function [1–3,10]. In the
context of the established role of AKT in dynamic modulation
of junctional complexes [6–9], we examined the impact of
GUCY2C signaling on intestinal barrier integrity through AKT-
dependent regulation of junctional complex components.
Materials and Methods
A detailed description of materials and methods used in this
paper can be found in Materials and Methods S1.
Animal models
Rosa-STOPflox-Guca2a-vil-Cre-ERT2 mice and corresponding ge-
notype controls lacking Rosa-STOPflox-Guca2a insert were generated
by crossbreeding vil-Cre-ERT2 (provided by Robine S., Institut
Curie-CNRS, France) with Rosa-STOPflox-Guca2a transgenic mice
(Thomas Jefferson University) (see Supplementary Information).
C57BL6 mice used in oral ST supplementation studies were
purchased from NIH (NCI-Frederick). Gucy2c2/2, Akt12/2,
Akt22/2 and corresponding wild type littermate mice were bred,
maintained, genotyped, and functionally characterized as de-
scribed in accordance with the Thomas Jefferson University
Animal Care and Use guidelines. This study was approved by The
Institutional Animal Care and Use Committee of Thomas
Jefferson University under approved animal protocol 315O, and
315K [15].
DSS colitis
8 weeks old male or female mice were treated with 3 or 3.5%
(w/v) DSS (Sigma-Aldrich) in their drinking water for 7 d followed
by normal access to water (see Materials and Methods S1). Colitis
severity was evaluated by body weight, mortality, and colon
length, as well as histology scores. Colon length is a morphometric
measure of the degree of colonic inflammation and correlates with
pathologic changes related to colitis severity [20].
Histopathology scores
Colon tissues were fixed in 10% buffered formalin, processed
and embedded in paraffin. Five mm tissue sections were stained
with hematoxylin-eosin (H&E). Seven sections in each mouse were
evaluated by two independent investigators blinded to genotype or
experimental condition. Each section was scored using the sum of
a 0–4 scale in both epithelial and mesenchymal compartments
based on established semiquantitative criteria (see Table S1) [21].
Barrier integrity
Littermate mice were gavaged with 200 mL of FITC-dextran
(75 mg/mL; 4 kD; Sigma-Aldrich) after an overnight fast.
Hemolysis-free serum was analyzed for concentration of FITC-
dextran by fluorimetry 90 min after gavage. Permeability of 4 kD
FITC-dextran across Caco2 (ATCC) monolayers was assessed
using the 24-mutiwell insert system (BD Biosciences).
DNA oxidation
DNA was extracted from leukocytes in Gucy2c+/+ and Gucy2c2/2
mice, and from hepatocytes in mice treated with ST or control
peptide followed by DSS administration, and stored at 220uC.
DNA oxidation was estimated by quantifying 8-hydroxydeoxy-
guanosine employing the OxiSelectTM Oxidative DNA Damage
ELISA Kit (Cell Biolabs, Inc., San Diego, CA).
Cell culture, adenovirus and retrovirus infection
Adenovirus-expressing AKT1 and myr-AKT were provided by
T. Chan (Thomas Jefferson University, PA). Retroviruses
expressing shRNA against AKT1 and empty vector were
produced from commercially available plasmids (Open Biosys-
tems). After retroviral infection, Caco2 cells were selected by
8.5 mg/mL puromycin (Invitrogen).
Immunoblot analyses
Protein was extracted from cells and tissues in M-PER reagent
(Pierce) supplemented with protease and phosphatase inhibitors
(Roche) and quantified by immunoblot analysis employing
antibodies to: occludin, claudin 1, claudin 2, claudin 3, claudin
4, JAM-A (Invitrogen); GAPDH, phospho-AKT (Cell Signaling).
Immunofluorescence
Distal colons were collected processed and embedded in
paraffin blocks and then cut into 5 mM slides as previous described
[15]. Tight junctions were stained by anti-claudin 4 antibody
(Invitrogen) and epithelial cells were outlined by anti-b-catenin
antibody (Santa Cruz Biotechnology). Nuclei were counterstained
by DAPI.
Microarray analyses
Microarray analyses, using the Affymetrix Mouse 430 2.0 39-
IVT platform, were performed on RNA extracted from intestine
of Gucy2c+/+ and Gucy2c2/2 littermates (n = 4 each) [15]. All
data is MIAME compliant and that the raw data has been
deposited in GEO, GeneExpressionOmnibus: a public functional
genomics data repository supporting MIAME compliant submis-
sion, http://www.ncbi.nlm.nih.gov/geo/.
Statistical analyses
Statistical significance was determined by unpaired two-tailed
Student’s t test. Body weight and survival were analyzed by
ANOVA unless otherwise specified. Results represent means 6
SEM from at least 3 animals or 3 experiments performed in
triplicate unless otherwise indicated.
Results
Eliminating Gucy2c signaling globally altered the expression of
the family of 74 canonical tight junction-associated genes in
Gucy2c2/2, compared to Gucy2c+/+, mice (Figure 1A; P = 0.029).
Global changes in mRNA expression were associated with
decreased steady-state levels of key tight junction proteins in
Gucy2c2/2 mice, including occludin, claudin 2, claudin 4 and
JAM-A (Fig. 1B, Data S1). Reductions in these structural
components were associated with reduced formation of junctional
complexes between epithelial cells (Fig. 1C). Moroever, junctional
complexes between adjacent enterocytes in Gucy2c2/2 mice
appeared centrally patent, compared to occluded junctions in
Gucy2c+/+ mice (Fig. 1D). These changes in junctional complexes
were associated with macromolecular hyperpermeability in
Gucy2c2/2, compared to Gucy2c+/+, mice (Fig. 1E).
GUCY2C, Mucosal Barrier, and Genotoxicity
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Beyond its effect on physiological barrier integrity, eliminating
GUCY2C signaling increased vulnerability to chemically-induced
disruption of the intestinal epithelial barrier. Oral administration
of dextran sulfate sodium (DSS) to mice disrupts the epithelial
barrier, in part by altering expression of tight junction proteins
[22], producing intestinal hyperpermeability and translocation of
lumenal contents across the mucosa [1–3]. In turn, barrier
disruption bridging the normally segregated mucosal and systemic
compartments produces secondary activation of innate and
adaptive immune responses, immune cell recruitment, and colitis
[1–3]. DSS induced colitis with a 3-fold greater severity, quantified
by maximum weight loss, in Gucy2c2/2, compared to Gucy2c+/+,
mice (Fig. 2A). Also, DSS colitis was associated with .80%
mortality in Gucy2c2/2 mice, compared to Gucy2c+/+ mice which
exhibited 100% survival (Fig. 2B). Gross and histological
pathology revealed that DSS-induced weight loss and mortality
was associated with inflammatory shortening of the colon (Fig. 2C)
and immune cell infiltration disrupting intestinal architecture
(Fig. 2D, E) in Gucy2c2/2, compared to Gucy2c+/+, mice.
Conversely, enhancing GUCY2C signaling defends the integrity
of the intestinal epithelial barrier from disruption by DSS,
preventing the associated colitis. Guca2a+ mice constitutively
express GUCA2A specifically in epithelial cells across the
rostral-caudal axis of the intestine when induced by tamoxifen
Figure 1. GUCY2C regulates intestinal barrier integrity. (A) Comparison of mRNA expression of genes associated with the canonical tight
junction pathway (KEGG 04530) of Gucy2c+/+ and Gucy2c2/2 mice (n = 4, p = 0.029). (B) Immunoblot analysis of tight junction proteins from the distal
colon of 12 week old Gucy2c+/+ and Gucy2c2/2 mice. Data represent means of n$76SEM. (C) Immunofluorescence staining of claudin 4 from the
distal colon of 12 week old Gucy2c+/+ and Gucy2c2/2 mice. (Nucleus-DAPI, b-catenin-red, Claudin 4-green; 1,0006). (D) Transmission electron
microscopy of tight junction complexes from jejuna of 12 week old Gucy2c+/+ and Gucy2c2/2 mice (25,0006). (E) FITC-dextran was administered by
oral gavage to age-matched Gucy2c+/+ and Gucy2c2/2 mice after an overnight fast. Serum fluorescence was analyzed 90 min after gavage. One
representative experiment of three (n = 3). *, p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0031686.g001
GUCY2C, Mucosal Barrier, and Genotoxicity
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(see Methods). Basal mucosal integrity, quantified by intestinal
permeability, was enhanced in Guca2a+, compared to control, mice
(Fig. 3A). Further, Guca2a+ mice resisted barrier disruption and
colitis induced by DSS compared to wild-type mice, quantified by
weight loss (Fig. 3B), survival (Fig. 3C), colon length (Fig. 3D), and
inflammatory cell infiltration disrupting intestinal architecture
(Fig. 3E, F). Results with the genetic model were confirmed with a
complementary pharmacological model in which mice were orally
administered the GUCY2C ligand ST. Like constitutive expres-
sion of the native paracrine hormone GUCA2A, oral administra-
tion of the bacterial peptide ST enhanced basal barrier integrity
(Fig. 4A) and opposed barrier disruption and colitis induced by
DSS (Fig. 4B–F).
There is an established relationship between disruption of the
epithelial barrier associated with local inflammation and the
production of systemic genotoxic insult, including DNA damage
reflecting reactive oxygen species that underlie tumor initiation
and progression [11]. Impairment of basal epithelial barrier
integrity in Gucy2c2/2 mice was associated with increased extra-
intestinal oxidative DNA damage in leukocytes, compared to
Gucy2c+/+ mice (Fig. 5A). Conversely, enhancing barrier integrity
with oral ST reduced hepatic oxidative DNA damage in mice
Figure 2. GUCY2C-deficiency increases susceptibility to DSS-induced colitis. Gucy2c+/+ and Gucy2c2/2 male mice were administered 3%
DSS in drinking water for 7 d to disrupt the epithelial barrier and induce colitis. Severity of colitis was analyzed by (A) body weight (n = 11) and (B)
survival (n$11). (C) Colon length was measured from the colocecal junction to the anal verge on day 12 (5 d post-DSS exposure) to quantify chronic
inflammation. (D) Histological sections obtained from jejunum and distal colon on day 12 were stained with H&E and scored for epithelial and
mesenchymal inflammation. Each point represents one mouse. (E) Representative H&E colon sections (206). Data are mean 6 SD (in C) and SEM (in
D) obtained from one of three independent experiments. **, p,0.01, ***, p,0.001.
doi:10.1371/journal.pone.0031686.g002
GUCY2C, Mucosal Barrier, and Genotoxicity
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treated with DSS (Fig. 5B). Impaired basal epithelial barrier
integrity producing systemic genotoxicity was associated with
spontaneous extra-intestinal tumorigenesis, including tumors in
mesenteric lymph nodes, livers, and lungs, in 50% of Gucy2c2/2
mice, but in only 10% of Gucy2c+/+ mice (Fig. 5C). Moreover,
elevated basal systemic genotoxicity reflecting barrier corruption
potentiated induction of hepatoma by the chemical carcinogen
azoxymethane (AOM) in Gucy2c2/2, but not in Gucy2c+/+, mice
(Fig. 5D).
GUCY2C modulates homeostatic processes by opposing AKT1
phosphorylation and downstream signaling in intestine and
colorectal cancer [15]. In the context of established AKT
modulation of junctional complexes [6–9], steady-state levels of
the tight junction proteins occludin and claudin 4, but not claudin
2 or JAM-A, were restored to those in wild type epithelial cells by
normalizing phospho-AKT1 levels in Gucy2c2/2Akt1+/2 mice
(Fig. 6A). Restoration of occludin and claudin 4 was associated
with reconstitution of intestinal barrier integrity characteristic of
wild type mice by reducing AKT1, but not AKT2, expression in
Gucy2c2/2 mice (Fig. 6B).
Normalizing phospho-AKT1 levels in Gucy2c2/2Akt1+/2 mice
mimics the effect of GUCY2C on AKT1 in Caco2 human
intestinal epithelial cells, an established in vitro model of the
intestinal barrier [23]. Stimulating GUCY2C with ST reduced
phospho-AKT1, an effect recapitulated by the downstream
GUCY2C effector, cGMP (Fig. 6C). ST enhanced the barrier
Figure 3. Constitutive GUCA2A expression in intestine suppresses DSS-induced colitis. Constitutive expression of GUCA2A was initiated
by Cre recombinase expressed in intestinal epithelial cells after 5 days of IP tamoxifen administration in ROSA-Guca2a6Vil-Cre/ERT2 male mice. Two
days later, 3% DSS was administrated for 7 d to induce colitis. (A) Intestinal macromolecular permeability was assessed on day 10 (3 d post-DSS
exposure) by serum fluorescence 90 min after FITC-dextran gavage (n$5). Severity of colitis was quantified by (B) body weight and (C) survival
(n$15). Data represent one of three independent experiments. Inflammation was quantified by (D) colon length and (E) histological score on day 10
(n$5). Each point represents one mouse. (F) Representative H&E colon sections (206). Data are mean 6 SEM. *, p,0.05.
doi:10.1371/journal.pone.0031686.g003
GUCY2C, Mucosal Barrier, and Genotoxicity
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properties of these cells, decreasing the permeability of Caco2
monolayers (Fig. 6D), reproducing the in vivo effect of ST on
intestinal permeability (Fig. 4A). The effect of ST on Caco2
permeability was mimicked by reducing AKT1 expression using a
target-specific siRNA, recapitulating the effects of genetic
knockdown of AKT1 in Gucy2c2/2Akt1+/2 mice (Fig. 4B).
Conversely, the effect of ST on Caco2 permeability was eliminated
by a constitutively active AKT1 mutant, MyrAKT1 (Fig. 6D).
Moreover, reducing the expression of AKT1 in Caco2 cells using a
target-specific shRNA reproduced the effects of GUCY2C
signaling on steady-state levels of occludin and claudin 4, but
not claudin 2 or JAM-A (Fig. 6E), precisely recapitulating the
effects of GUCY2C and AKT1 on junctional proteins in Gucy2c2/2
Akt1+/2 mice (Fig. 6A).
Discussion
Disruption of intestinal barrier integrity has profound patho-
physiological consequences and there is an emerging recognition
of the contribution of the ‘‘leaky gut’’ and intestinal hyperperme-
ability to human disease [1–3,10,24]. In part, intestinal barrier
integrity reflects dynamic modulation of tight junction complexes
through regulation of component proteins, including intracellular
steady-state concentrations and their assembly and membrane
Figure 4. GUCY2C ligand supplementation decreases intestinal permeability and susceptibility to DSS-induced colitis. C57B6 female
mice were administered control peptide (CP) or ST to examine the effect of GUCY2C activation on intestinal permeability after 14 d of oral ligand
supplementation. (A) Serum fluorescence was analyzed 90 min after FITC-dextran gavage (n = 21) following 6 d of ligand supplementation. (B, C)
Following 14 d of ST pre-conditioning, 3.5% DSS was administrated for 7 d to induce colitis which was quantified by (B) body weight and (C) survival.
Data represent one of two independent experiments. Severity of colitis was quantified by (D) colon length, measured on day 10 (3 d post-DSS
exposure), and gross anatomic analysis of colons from ST-, compared to CP-, preconditioned mice demonstrated normal stool formation (n = 21) and
(E) histological score on day 10. Each point represents one mouse. (F) Representative H&E colon sections (206). *, p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0031686.g004
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deployment [2,3]. These complexes are rate-limiting components
in transepithelial transport and primary determinants of mucosal
permeability [2,3,10]. Acquired or inherited impairment of this
barrier is at least necessary, if not sufficient, for abnormal
subepithelial exposure to lumenal antigens that provoke immune
responses underlying inflammatory bowel disease [1,2]. Beyond
these local effects, epithelial barrier dysfunction leading to cross-
compartmental exposure to environmental antigens may be one
necessary precondition for the development of systemic multi-
organ autoimmune diseases including type I diabetes, multiple
sclerosis, asthma, food allergy, hypersensitivity and cancer
[1–3,10,24]. These considerations underscore an unmet clinical
need for novel therapeutic approaches that defend intestinal
barrier integrity to prevent systemic disease.
While GUCY2C was originally identified as the intestinal
receptor for the diarrheagenic bacterial STs, its role in modulating
physiological fluid and electrolyte secretion emerged following the
discovery of the endogenous paracrine hormones GUCA2A and
GUCA2B [25]. Beyond fluid and electrolyte balance, recent
studies have revealed a role for GUCY2C in regulating
homeostatic programs that shape the dynamic crypt-villus axis.
GUCY2C regulates key cell cycle circuits, restricting cell division
Figure 5. GUCY2C modulates systemic genotoxicity and tumorigenesis. (A) Eliminating GUCY2C increases basal DNA oxidation in
leukocytes. Each point represents one mouse. (B) Oral ST supplementation decreases DSS-induced hepatic genotoxicity. Gucy2c+/+ mice were
preconditioned with oral ST for 6 d, and then treated with 3.5% DSS for 7 d, followed by quantification of DNA oxidation in liver on days 10 (n$5)
and 13 (n$2; 3 and 6 d post-DSS exposure). Data represent mean 6 SD. (C) Gucy2c2/2 mice exhibited a higher incidence of spontaneous tumors
comparing with age-matched 2-year-old Gucy2c+/+mice (n$14, p = 0.02). (D) The carcinogen AOM induced hepatoma in Gucy2c2/2, but not Gucy2c+/+,
mice (n$10, p = 0.04). C and D are analyzed by two-sided Fisher’s exact test. *, p,0.05.
doi:10.1371/journal.pone.0031686.g005
GUCY2C, Mucosal Barrier, and Genotoxicity
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Figure 6. GUCY2C regulation of barrier integrity is AKT1-dependent. (A) Immunoblot analysis of tight junction proteins from jejuna of 12
week-old mice (n$7). Data represent means 6 SEM. Blue asterisks compare results to Gucy2c+/+, black asterisks compare results to Gucy2c2/. (B)
Intestinal permeability was examined by serum fluorescence 90 min after FITC-dextran gavage. Each point represents one mouse. (C) Regulation of
AKT phosphorylation by GUCY2C signaling in Caco2 human colon cancer cells was examined by immunoblot analysis. Data represent means 6 SEM
of 3 experiments done in duplicate. (D) AKT1 signaling in Caco2 cells was manipulated by adenovirus-delivered AKT1 (WTAKT1), constitutive active
AKT1 mutant (MyrAKT1), or siRNA against AKT1 (siAKT1). Two days after infection, cells were treated with ST for 6 d. Barrier permeability was
examined by FITC-dextran diffusion. Data represent mean 6 SEM obtained from one of five experiments done in triplicate. (E) Tight junction protein
expression was examined by immunoblot analysis in Caco2 cells stably expressing empty vector (MSCV) or shRNA against AKT1 (shAKT1) after 6 d of
ST treatment. Data represent means 6 SEM of three experiments done in duplicate. Blue asterisks compare results to MSCV-PBS, black asterisks
compare results to MSCV-ST. *, p,0.05, **, p,0.01, ***, p,0.001. In C–E, statistical analyses were compared to PBS control.
doi:10.1371/journal.pone.0031686.g006
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as epithelial cells transition from the proliferating crypt to the
differentiated villus compartment [13–16]. Also, GUCY2C drives
differentiation along the secretory lineage, amplifying the
production of goblet, Paneth and enteroendocrine cells [13].
Further, GUCY2C signaling shifts metabolic programming from
glycolytic to mitochondrial oxidative metabolism as cells transition
from proliferating to differentiated compartments [15]. Moreover,
GUCY2C modulates DNA damage sensing and repair, protecting
chromosomal integrity [13,14]. Disruption of these homeostatic
processes, reflecting universal early loss of expression of GUCA2A
and GUCA2B which silences GUCY2C, contributes to hyper-
proliferation and chromosomal instability underlying intestinal
tumorigenesis in animals and humans [16–19].
The present studies extend this homeostatic role of GUCY2C
beyond proliferation, differentiation, migration, DNA damage
sensing and repair, and metabolism to maintenance of macromo-
lecular permeability and the intestinal barrier. Elimination of
GUCY2C signaling produced basal macromolecular hyperperme-
ability and potentiated barrier disruption resulting in colitis
induced by DSS [26]. Conversely, genetic or pharmacological
induction of GUCY2C signaling reduced basal permeability and
DSS-induced hyperpermeability and inflammation. Results in
mouse models were recapitulated in monolayers of human
intestinal epithelial cells in vitro, in the absence of other
confounding (patho)physiological mechanisms like inflammation,
demonstrating a primary mechanistic role for GUCY2C in
regulating the epithelial barrier and macromolecular permeability.
Moreover, protection of the epithelial barrier by GUCY2C in vivo
and in vitro was associated with alterations in steady state
concentrations of tight junction proteins, including occludin and
claudin 4. Regulation of steady-state concentrations of these
components are one established mechanism modulating the
dynamic assembly and deployment of tight junction complexes,
barrier integrity and macromolecular permeability [1–3,10,27].
Integration of crypt-villus homeostatic programs mediated by
GUCY2C is coordinated through AKT1 [15]. Ligand activation
of GUCY2C and accumulation of cGMP produces dephosphor-
ylation of AKT1, modulating downstream signaling circuits
regulating proliferation and metabolism [15]. In the present
study, homeostatic regulation of epithelial barrier function and
permeability by GUCY2C was mediated by AKT1. In that
context, specifically reducing AKT1, but not AKT2, blocked
alterations in occludin and claudin 4, but not JAM-A and claudin
2, and macromolecular hyperpermeability induced by eliminating
GUCY2C signaling in mice. Further, in monolayers of human
intestinal epithelial cells in vitro, eliminating AKT1 expression
induced steady state levels of occludin and claudin 4, but not JAM-
A and claudin 2, and barrier function to levels achieved by ST
activation of GUCY2C. Moreover, a constitutively activated form
of AKT1 produced resistance to, while eliminating AKT1
expression from these cells mimicked, the effects of GUCY2C
activation on epithelial cell permeability. Together, these results
demonstrate a key mechanistic role for suppression of AKT1
signaling in the regulation of epithelial cell barrier function by
GUCY2C. These results reinforce the established role of AKT in
regulating the expression of junctional proteins, disrupting
epithelial cell membrane complexes, and inducing barrier
dysfunction [6–9]. Further, they identify occludin and claudin 4,
but not JAM-A and claudin 2, as specific downstream targets of
AKT1 contributing to the regulation of epithelial barrier
permeability in vitro and in vivo. They underscore the integrated
homeostatic role of GUCY2C signaling, centrally coordinated
through AKT, in regulating intestinal epithelial structure and
function [12–15].
There is an established mechanistic relationship between
disruption of the intestinal epithelial barrier, inflammation
resulting from systemic immune exposure to normally compart-
mentalized lumenal antigens, and the generation of reactive
oxygen species producing DNA damage and genotoxic stress [28].
In turn, reactive oxygen species producing DNA damage comprise
one mechanism contributing to tumorigenesis generally, and to the
evolution of colon cancer in the context of inflammatory bowel
disease, specifically [11,28]. Importantly, there is emerging
recognition that this oxidative stress extends beyond the primary
site of barrier disruption and inflammation, and is disseminated
systemically [11]. Indeed, genetic or chemical disruption of the
intestinal barrier associated with inflammation produces systemic
DNA damage and genotoxic stress, including in circulating
leukocytes [11]. Here, barrier disruption and hyperpermeability
produced by silencing GUCY2C was associated with elevated
levels of oxidative DNA damage in circulating leukocytes.
Conversely, defending barrier integrity and restricting permeabil-
ity by activating GUCY2C with oral ST decreased systemic
genotoxicity in hepatocytes produced by DSS. Further, systemic
genotoxicity produced by barrier disruption reflecting GUCY2C
silencing was associated with increased spontaneous and carcin-
ogen-induced extra-intestinal tumorigenesis, specifically in lung,
liver and lymph nodes. In the context of the role of GUCY2C as a
tissue-specific tumor suppressing receptor [12], the present
observations expand that function beyond transformation in the
colorectum [29], to neoplasia in lymph nodes, liver, and lung
through maintenance of epithelial barrier integrity. Moreover, it is
tempting to speculate that loss of paracrine hormone expression
and silencing of GUCY2C in inflammatory bowel disease [30]
produces systemic genotoxicity which contributes to the pattern of
extra-intestinal cancer in these patients specifically in lymph nodes,
liver, and lung [31,32].
The present study further clarifies the evolving role of the
GUCY2C paracrine hormone system in modulating the intestinal
barrier. A role for GUCY2C in regulating epithelial barrier
function was recently demonstrated, and the present work
confirms that phenomenon [33]. Those studies revealed that
silencing GUCY2C disrupted the barrier and induced inflamma-
tion, associated with production of interferon gamma and IL-12
[33]. In turn, those events were associated with increased
expression of epithelial cell myosin light chain kinase, an
established regulator of tight junction structure and function,
and suppression of JAM-A and claudin 2 expression. These
phenomena were presumed to be the molecular mechanisms
mediating GUCY2C-dependent barrier disruption. However,
canonical regulation of myosin light chain phosphorylation by
cGMP is mediated by myosin light chain phosphatase, rather than
myosin light chain kinase [34]. Moreover, these observations are
complicated by the contribution of inflammatory cytokines,
including interferon gamma, to regulation of expression of myosin
light chain kinase in intestinal epithelial cells in vivo and in vitro
[2,3]. Thus, the contribution of these components may not reflect
the primary mechanism underlying GUCY2C regulation of
barrier integrity but, rather, an epiphenomenon related to the
associated inflammation [33]. In contrast, the present study
demonstrates a mechanistic role for GUCY2C as a primary
modulator of the intestinal epithelial barrier, mediated by AKT1,
occludin and claudin 4, but not JAM-A and claudin 2, in mouse
models in vivo, and in human intestinal cell monolayers in vitro in
the absence of confounding by inflammation.
Paradoxically, subsequent work from the same group suggested
that eliminating GUCY2C signaling protects the intestinal mucosa
from inflammatory injury [35]. In that study, barrier disruption by
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DSS induced greater inflammation, tissue damage, and mortality
in Gucy2+/+, compared to Gucy2c2/2, mice [35]. These results
stand in striking contradistinction to earlier reports by this group
[33]. Indeed, while baseline inflammation was elevated in
Gucy2c2/2 mice previously [33], here these mice exhibited
reduced levels of inflammatory cytokines including interferon
gamma [35]. Similarly, while barrier disruption produced
exaggerated responses in Gucy2c2/2 mice previously [33], here
barrier disruption produced disease of greater severity in Gucy2c+/+
mice [35]. Beyond the inconsistencies in these observations from
the same group, they stand in striking contrast to the results
presented herein, demonstrating that GUCY2C signaling defends
mucosal integrity against barrier disruption and colitis produced
by DSS. The importance of these inconsistencies can best be
appreciated by their respective therapeutic implications. On the
one hand, if cGMP signaling exacerbates barrier disruption
resulting in inflammation, then GUCY2C antagonists could be
therapeutic in inflammatory bowel disease. Conversely, if cGMP
signaling defends the barrier and prevents ensuing inflammation,
then GUCY2C agonists could be a significant addition to the
therapeutic armamentarium against inflammatory bowel disease.
While the source remains unclear, one possibility for these and
past inconsistencies [14,36] is the animal models used for genetic
comparisons [37]. Here, all comparisons between Gucy2c2/2 and
Gucy2c+/+ mice were performed with matched colony mates. This
experimental design reflects our observation that wild type mice
obtained commercially exhibit increased susceptibility to DSS
compared to wild type mice from our colony (See Figure S1). If
earlier studies [35,36] compared the behavior of Gucy2c2/2 or
Guca2a2/2 mice to commercially-available wild type mice,
inconsistent results could reflect differences in genetic or
environmental characteristics beyond the specific genes targeted
in the models. The present study demonstrates the role of the
GUCY2C paracrine axis in barrier regulation using multiple
genetic models that either eliminate receptor circuits or constitu-
tively express paracrine ligands, with appropriate intra-colony
controls, complemented by studies of oral GUCY2C ligand
efficacy conducted in wild type mice from an independent colony.
This evidence strongly supports a role for the GUCY2C paracrine
axis in maintaining barrier integrity, and the therapeutic value of
GUCY2C ligands in preventing and treating barrier disruption
and inflammatory bowel disease.
Beyond proliferation, metabolism, and chromosomal integrity,
the present studies reveal an additional dimension of AKT1-
dependent epithelial homeostatic regulation by GUCY2C. Indeed,
it is tempting to speculate that one essential function of GUCY2C
signaling is maintenance of intestinal barrier integrity. In that
context, regulation of epithelial tight junctions contributing to
macromolecular permeability described here can be added to
other established GUCY2C functions, including fluid and
electrolyte secretion accelerating lumenal clearance; differentiation
of Paneth cells producing antimicrobial peptides; and differenti-
ation of goblet cells producing intestinal mucus that contribute to
the separation of systemic and environmental compartments
across the mucosal interface [13]. The pathophysiological
significance of this role in intestinal barrier protection is
underscored by the impact of GUCY2C signaling on colitis and
systemic genotoxicity and tumorigenesis. In turn, these consider-
ations highlight the translational opportunities for GUCY2C
ligands in the prevention and treatment of inflammatory bowel
disease and extra-intestinal malignancies. This therapeutic poten-
tial is underscored by the recent advancement of the oral
GUCY2C ligand linaclotide for FDA approval for the treatment
of constipation-type irritable bowel syndrome [38].
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Figure S1 Environmental effects on DSS-induced colitis.
8 week old C57JBL6 mice purchased from NCI (black circles) and
in-house C57JBL6 mice generated from Gucy2c+/2 colony (blue
circles) were fed with 3% DSS for 7 d followed by regular drinking
water. Body weight (n$11) was measured as an indicator for
severity of colitis. Values are given as percentage of body weight
on day 06SEM. *, p,0.05.
(PDF)
Table S1 Histopathology score table. Semiquantitative
histopathological scoring system based on the criteria presented
in the table was used by two independent investigators blinded to
genotypes or experimental condition to assess severity of colitis.
Scores from epithelium and mesenchyme were summed to
determine the degree of inflammation for each section. Mean
scores of at least seven sections per animal were presented in
figures.
(PDF)
Materials and Methods S1 Detailed experimental pro-
cedures and reagents used in this manuscript.
(PDF)
Data S1 Result of KEGG pathway 04530 (Tight Junction)
between C57Bl6 Gucy2c+/+ and Gucy2c2/2 mice.
(HTML)
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